Companies
Life Sciences
MIRA Pharmaceuticals, Inc.
Engineering Cannabinoids to Treat Neurodegenerative Diseases and Chronic Pain
by
KAREN STERLING, PhD, CFA
We initiate coverage on MIRA Pharmaceuticals with a Buy rating and a DCF-based 24-month price target of $10.00. MIRA is a preclinical development-stage life sciences company with two neuroscience prog...
Read Report
March 5, 2025
MIRA Pharmaceuticals Announces Upcoming Start of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Milestone marks MIRA’s transition from pre-clinical to clinical stage company. Downgrade from BUY to HOLD based on delays in MIRA’s clinical development timeline and a more challenging competitive lan...
by
KAREN STERLING, PhD, CFA
Read Update
December 20, 2024
MIRA Pharmaceuticals Files Investigational New Drug Application for Ketamir-2 with FDA
Achieving a long-awaited milestone, MIRA prepares to become a clinical-stage company in early 2025.

On December 19, 2024, MIRA Pharmaceuticals announced the filing of its first investigational new dr...
by
KAREN STERLING, PhD, CFA
Read Update
November 14, 2024
MIRA Pharmaceuticals Reports Third Quarter 2024 Earnings
MIRA Pharmaceuticals reported financial results for the third quarter ended September 30, 2024. As is typical for a preclinical-stage company, revenue was $0, on par with our estimates. GAAP EPS of $(...
by
KAREN STERLING, PhD, CFA
Read Update
October 30, 2024
MIRA Pharmaceuticals Announces Superiority of Ketamir-2 to Gabapentin (Neurontin) in Preclinical Studies
MIRA Pharmaceuticals’s stock experienced significant price and volume increases following the company’s announcement that its Ketamir-2 product candidate induced near-complete normalization of pain se...
by
KAREN STERLING, PhD, CFA
Read Update
August 27, 2024
MIRA Pharmaceuticals Files 10Q, Reports on Preclinical Progress with Ketamir-2
MIRA Pharmaceuticals reported financial results for the second quarter ended June 30, 2024. As is typical for a preclinical-stage company, revenue was $0, on par with our estimates. GAAP EPS of $(0.11...
by
KAREN STERLING, PhD, CFA
Read Update
July 24, 2024
MIRA Pharmaceuticals on Track to Advance Its Two Preclinical Assets Toward Clinical Trials
Shares of MIRA Pharmaceuticals nearly tripled in value since July 19 on news about the continued preclinical success of its investigational drug candidate, Ketamir-2. The newly released data from in v...
by
KAREN STERLING, PhD, CFA
Read Update
April 19, 2024
Engineering Cannabinoids to Treat Neurodegenerative Diseases and Chronic Pain
We re-initiate coverage on MIRA Pharmaceuticals with a Buy rating and a DCF-based 21-month price target of $10.00. MIRA isa preclinical development-stage life sciences company with two neuroscience pr...
by
KAREN STERLING, PhD, CFA
Read Update
Get Kingswood Equity Research reports delivered right to your inbox
Enter your contact information below and we’ll 
send you future reports and updates to existing reports so you’re always up to date with our latest research.